Precision lung cancer therapy design through multiplexed adapter measurement

通过多重适配器测量进行精准肺癌治疗设计

• 批准号: 10246394
• 负责人: ERIC B. HAURA
• 金额: $ 45.94万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-25 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10246394
• 关键词: Adaptor Signaling Protein; Automobile Driving; Biological Assay; Bypass; Cell Line; Cell Survival; Cells; Combined Modality Therapy; Complement Receptor; Detection; Development; Drug Combinations; Elements; Epidermal Growth Factor Receptor; Event; Genomics; Immune; Ligands; Ligation; Link; Malignant neoplasm of lung; Maps; Measurement; Measures; Mediating; Methods; Mission; Modeling; Mutation; Pathway interactions; Phosphatidylserines; Proteins; Public Health; RIPK1 gene; Receptor Activation; Receptor Protein-Tyrosine Kinases; Regulation; Research; Resistance; Role; Signal Transduction; Statistical Models; Testing; Therapeutic; United States National Institutes of Health; Work; autocrine; axl receptor tyrosine kinase; base; cancer therapy; improved; in vivo; individual patient; mutant; neoplastic cell; new therapeutic target; patient derived xenograft model; predictive modeling; receptor; receptor expression; resistance mechanism; response; targeted treatment; therapy design; therapy resistant; tumor; tumor xenograft

Project Summary Combination therapy holds considerable promise for overcoming intrinsic and acquired resistance to targeted therapies but will rely on our ability to precisely identify the best drug combination for particular tumors. While immense focus exists on using genomic information to direct therapeutic approach, many resistance mechanisms do not rely on genetic changes and, in fact, can arise from entirely tumor-extrinsic factors within the microenvironment. For example, though the receptor tyrosine kinase (RTK) AXL is widely implicated in resistance to targeted therapies such as those directed against EGFR, its regulation by phosphatidylserine, as opposed to mutation, amplification or autocrine ligand, make identifying the tumors that will respond to AXL- targeted therapy especially challenging. We propose to study both downstream and receptor-proximal signaling during bypass resistance mediated by AXL, and then across a wider panel of RTKs. Integrating these measurements with quantitative modeling will identify the connectivity between receptors, interacting adapters, and downstream signaling events, thereby defining the essential set of signaling network changes required for tumor cell survival in response to targeted therapeutics. We will then apply this understanding by measuring RTK-adapter interaction using proximity ligation to predict the RTKs driving bypass resistance and test these predictions in a panel of patient-derived xenograft tumors. This work will considerably improve our ability to identify effective drug combinations by (a) developing a mechanism-based assay for identifying which among many RTKs tumor cells are relying upon for survival, (b) improving our basic understanding of exactly how network-level bypass resistance arises due to activation of non-targeted RTKs both at the receptor-proximal and downstream signaling layer, and (c) expanding our understanding of the RTK AXL with links to resistance, tumor spread, and immune avoidance.

项目摘要 联合疗法具有克服对目标的内在和获得的抵抗力的巨大希望 疗法，但将依靠我们精确鉴定特定肿瘤的最佳药物组合的能力。尽管 非常关注使用基因组信息来指导治疗方法，许多抗药性 机制不依赖遗传变化，实际上，机制可能是由完全由肿瘤因素引起的 微环境。例如，尽管受体酪氨酸激酶（RTK）AXL广泛涉及 对针对靶向疗法的抗性，例如针对EGFR的疗法，其对磷脂酰丝氨酸的调节为 与突变，扩增或自分泌配体相反，使识别会对AXL-反应的肿瘤 有针对性的疗法特别具有挑战性。 我们建议在旁路电阻期间研究下游和受体 - 耐氧气信号 由AXL介导，然后穿过较宽的RTK面板。将这些测量与定量整合 建模将识别受体，相互作用适配器和下游信号之间的连通性 事件，从而定义了肿瘤细胞存活所需的基本信号网络的变化 对靶向治疗药的反应。然后，我们将通过测量RTK-ADAPTER应用此理解 使用接近连接的相互作用来预测驱动旁路电阻的RTK，并在A中测试这些预测 患者衍生异种移植肿瘤的面板。 这项工作将大大提高我们通过（a）开发识别有效药物组合的能力 一种基于机制的测定法，用于识别许多RTK肿瘤细胞中哪些依赖于生存的测定法 （b）提高我们对网络级旁路阻力的准确理解 在受体 - 阳性和下游信号层处的非靶向RTK，以及（c）扩展我们的 了解RTK AXL具有与耐药性，肿瘤扩散和免疫避免的联系。

项目成果

Bidirectional Adaptive Signaling between cancer and stromal cells: mechanisms and therapeutics.

• DOI: 10.1080/14789450.2018.1521276
• 发表时间: 2018-09
• 期刊: Expert review of proteomics
• 影响因子: 3.4
• 作者: Boutchueng-Djidjou M;Rix U;Haura EB
• 通讯作者: Haura EB

Dissecting signaling regulators driving AXL-mediated bypass resistance and associated phenotypes by phosphosite perturbations.

剖析通过磷酸位点扰动驱动 AXL 介导的旁路抗性和相关表型的信号调节因子。

• DOI: 10.1101/2023.10.20.563266
• 发表时间: 2023
• 期刊: bioRxiv : the preprint server for biology
• 作者: Creixell,Marc;Taylor,ScottD;Gerritsen,Jacqueline;Bae,SongYi;Jiang,Mingxuan;Augustin,Teresa;Loui,Michelle;Boixo,Carmen;Creixell,Pau;White,ForestM;Meyer,AaronS
• 通讯作者: Meyer,AaronS

Integrated Proteomics-Based Physical and Functional Mapping of AXL Kinase Signaling Pathways and Inhibitors Define Its Role in Cell Migration.

• DOI: 10.1158/1541-7786.mcr-21-0275
• 发表时间: 2022-04-01
• 期刊: Molecular cancer research : MCR
• 作者: Majumder A;Hosseinian S;Stroud M;Adhikari E;Saller JJ;Smith MA;Zhang G;Agarwal S;Creixell M;Meyer BS;Kinose F;Bowers K;Fang B;Stewart PA;Welsh EA;Boyle TA;Meyer AS;Koomen JM;Haura EB
• 通讯作者: Haura EB